InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS™ and MGuard™ Prime Products in Vietnam
April 30, 2018 07:34 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, April 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million
April 03, 2018 10:28 ET
|
InspireMD, Inc.
TEL AVIV, Israel, April 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces First Patient Treated with CGuard™ EPS in India
March 05, 2018 08:07 ET
|
InspireMD, Inc.
Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard™ EPS TEL AVIV, ISRAEL, March 05, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader...
InspireMD, Inc. Announces Pricing of Public Offering of Common Stock
February 27, 2018 07:00 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL , Feb. 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea
February 22, 2018 10:16 ET
|
InspireMD, Inc.
Solvit Medical to fund all regulatory, registration and reimbursement submissions TEL AVIV, ISRAEL, Feb. 22, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in...
InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India
February 20, 2018 09:00 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Feb. 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard™ EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year
February 14, 2018 07:30 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Feb. 14, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD's CGuard Embolic Prevention System Featured in a Second Live Case Transmission at LINC 2018 by Leading Interventional Cardiologists
January 31, 2018 08:31 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 31, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard™ Embolic Prevention System Featured in Successful Live Case Transmissions at LINC 2018 by Leading Vascular Surgeons
January 30, 2018 08:19 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018
January 26, 2018 10:11 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...